Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus

Clinical Infectious Diseases

Volumn 42, Issue 1, 2006, Pages 126-131

  Saag, Michael S ^a,b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ANTIVIRAL ACTIVITY; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTHRALGIA; ASTHENIA; BIOEQUIVALENCE; CLINICAL TRIAL; COUGHING; DEPRESSION; DIARRHEA; DOSE CALCULATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; FATTY LIVER; FEVER; HEADACHE; HEALTH CARE ORGANIZATION; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; INSOMNIA; LACTIC ACIDOSIS; MEDICAL SOCIETY; MYOPATHY; NAUSEA; NEUROPATHY; PHARYNGITIS; PRIORITY JOURNAL; REVIEW; RHINITIS; SKIN DISCOLORATION; SUPERINFECTION; VOMITING;

ANTI-RETROVIRAL AGENTS; DEOXYCYTIDINE; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 29244431976     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/498348     Document Type: Review

References (49)

1. Schinazi RF, McMillan A, Cannon D, et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36:2423-31.
2. Furman PA, Davis M, Liotta DC, et al. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother 1992; 36:2686-92.
3. Furman PA, Reardon JE, Painter GR. The role of absolute configuration in the anti-HIV and anti-HBV activity of nucleoside analogs. Antivir Chem Chemother 1995; 6:345-55.
4. Paff MT, Averett Dr, Prus KL, Miller WH, Nelson DJ. Intracellular metabolism of (-) and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine in HepG2 derivative 2.2.15(subclone P5A)cells. Antimicrob Agents Chemother 1994; 38:1230-8.
5. Wilson JE, Martin JL, Borroto-Esoda K, Hopkins S, Painter G, Liotta DC and Furman PA. The 5′-triphosphates of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl] cytosine equally inhibit human immunodeficiency virus type 1 reverse transcriptase. Antimicrobic Agents Chemother 1993; 37:1720-2.
6. Wilson JE, Aulabaugh A, Caligan B, McPherson S, Wakefield JK, Jablonski S, Morrow, CD, Reardon JE, and Furman PA. Human immunodeficiency virus type-1 reverse transcriptase contribution of Met-184 to binding of nucleoside 5′-triphosphate. J Biol Chem 1996; 271: 13656-62.
7. Stein DS, Moore K. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001; 21:11-34.
8. Schinazi RF, McMillan A, Cannon D, et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2- (hydroxymethyl)-1,3-oxathiolane-5-yl] cytosine. Antimicrob Agents Chemother 1992; 36:2423-31.
9. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′ thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci 1993; 90:5653-6.
10. Schinazi RF, Lloyd RM, Nguyen M-H, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993; 37:875-81.
11. Mathez D, Schinazi RF, Liotta DC, Leibowitch J. Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro. Antimicrob Agents Chemother 1993; 37:2206-11.
12. Bridges EG, Dutschman GE, Gullen EA, Cheng Y-C. Favorable interaction of β-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem Pharmacol 1996; 51:731-6.
13. Feng JY, Anderson KS. Mechanistic studies show that (-)-emtricitabine-TP is a better inhibitor of HIV-1 reverse transcriptase than 1a-mivudine-TP. FASEB Journal 1999; 13:1511-7.
14. Jansen RW, Johnson LC, Averett DR. High-capacity in vitro assessment of antihepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrob Agents Chemother 1993; 37: 441-7.
15. Schinazi RF, Gosselin G, Abdesslem F, et al. Pure nucleoside enantiomers of B-2′3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob Agents Chemother 1994; 38:2172-4.
16. Emtricitabine [package insert]. Gilead Sciences.
17. Wang LH, Delehanty J, Hulett L, McCreedy B, Sommadossi JP, Rousseau F. High levels of intracellular emtricitabine-triphosphate correlate with the potent antiviral activity of emtricitabine in vivo [abstract LB-2.]. In: Program and abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). 1998.
18. Cammack N, Rouse P, Marr CL, et al. Cellular metabolism (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem Parmacol 1992; 43:2059.
19. Frick LW, Lambe CU, St John L, Taylor LC, Nelson DJ. Pharmacokinetics, oral bioavailability, and metabolism in mice and cynomolgus monkeys of (2′r,5′s)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine and agent active against human immunodeficiency virus and human hepatitis b virus. Antimicrob Agents Chemother 1994; 38:2722-9.
20. Chen CH, Cheng YC. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with anti-human immunodeficiency compound 2′, 3′-dideoxycytidine. J Biol Chem 1989; 264:11934-7.
21. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy by long-term zidovudine therapy. New Engl J Med 1990; 332:1098-105.
22. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
23. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333:1099-105.
24. Feng JY, Johnson AA, Johnson KA, Schinazi RF, Anderson KS, Furman PA. Insights into the molecular mechanism of mitochondrial toxicity of antiviral drugs [abstract P17]. In: Program and abstracts of the 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV (Toronto, Canada). 2000.
25. Frick LW, St John L, Taylor LC, et al. Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2- (hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis b virus. antimicrob. Agents Chemother 1993; 37:2285.
26. Schinazi RF, Boudinot FD, Ibrahim SS, Manning C, McClure HM, Liotta DC. Pharmacokinetics and metabolism of racemic 2′,3′-dideoxy-5-fluoro-3- thiacytidine in rhesus monkeys. Antimicrob Agents Chemother 1992; 36:2432-8.
27. Mondou E, Hinkle J, Shaw A, et al. Incidence of skin discoloration across phase 3 clinical trials of emtricitabine (FTC) in adults [poster 5916]. In: Program and abstracts of the XV International AIDS Conference (Bangkok, Thailand). 2004.
28. Delehanty J, Kahn J, Thompson M, et al. Selection of emtricitabine dose based on viral kinetics and pharmacokinetics in an accelerated clinical trial design [astract 12208]. In: Program and abstracts of the 12th Annual World AIDS Conference (Geneva, Switzerland). 1998:53.
29. Delehanty J, Wakeford C, Hulett L, et al. A phase I/II randomized controlled study of FTC versus 3TC in HIV-infected patients [abstract 16]. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago, IL). 1999.
30. Molina JM, Ferchal F, Rancinan C, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000; 182:599-602.
31. Molina JM, Perusat S, Ferchal F, et al. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment-naïve HIV-infected adults: 64 week follow-up of the ANRS091 trial [abstract 321]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago, IL). 2001.
32. Saag MS, Cahn P, Raffi F, et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naïve patients - a randomized trial. JAMA 2004;292:180-90.
33. Pozniak AL, Gallant J, DeJesus E, et al. Superior outcome for tenofovir DF, emtricitabine and efavirenz compared to fixed dose zidovudine/ lamivudine and EFV in antiretroviral naive patients [abstract WeOa0202]. In: Program and abstracts of the 3rd International AIDS Society Conference on Pathogenesis and Treatment (Rio de Janeiro, Brazil). 2005.
34. Van der Horst C, Sanne I, Wakeford C, Quinn J, Rousseau F. Two randomized, controlled, equivalance trials of emtricitabine (emtricitabine) to lamivudine (3TC) [abstract 18]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago, IL). 2001.
35. Bartlett J. Severe liver toxicity inpatients receiving two nucleoside analogues and a non-nucleoside reverse transcriptase inhibitor [abstract 19]. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago, IL). 2001.
36. Gish RG, Leung N, Wang C, et al. Antiviral activity, safety, and incidence of resistance in chronically infected hepatitis B patients (CHB) given once daily emtricitabine for 2 years [abstract 838]. In: Program and abstracts of the 53rd Annual Meeting of the American Association for the Study of Liver Diseases (Boston, MA). 2002.
37. Gish RG, Leung NWY, Wright TL, et al. Dose range study of pharmacokientics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46:1734-40.
38. Gish R, Wright T, Wang C, et al. HBeAg profile in patients with chronic HBeAg+ hepatitis B (CHB) treated with emtricitabine (FTC) for 1 year [abstract 40991]. In: Program and abstracts of the 52nd Annual Meeting of the American Association for the Study of Liver Diseases (Dallas, TX). 2001.
39. Wang C, Corey L, Leung N, et al. Antiviral activity of 48 weeks of emtricitabine (FTC) treatment in patients with HBeAg negative/HBV DNA positive chronic hepatitis B (CHB) [abstract 41043]. In: Program and abstracts of the 52nd Annual Meeting of the American Association for the Study of Liver Diseases (Dallas, TX). 2001.
40. Shiffman ML, Ng TM, Krastev Z, et al. A double-blind, placebo-controlled trial of emtricitabine (FTC, Emtriva) administered once-daily for treatment of chronic hepatitis B virus (HBV) infection [abstract 22]. In: Program and abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases (Boston, MA). 2004.
41. Raffi F, Snow A, Borroto-Esoda K, et al. Anti-HBV activity of emtricitabine (FTC) in patients co-infected with HIV and hepatitis B virus [abstract 215]. In: Program and abstracts of the 2nd International AIDS Conference on Pathogenesis and Treatment (Paris, France). 2003.
42. Harris J, Snow A, Borroto-Esoda K, et al. Emtricitabine therapy for hepatitis infection in HIV-1 patients co-infected with hepatitis B: antiviral response and genotypic findings in antiretroviral treatment naive patients [abstract 836]. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections (San Francisco, CA). 2004.
43. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992; 256:1783-90.
44. Mommeja Marin H, Leung N, Gish R, et al. Antiviral activity and incidence of resistance after treatment for two years with emtricitabine in patients with chronic hepatitis B [abstract 239]. In: Program and abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, CA). 2002.
45. Snow A, Lim SG, Gish R, et al. Correlation between baseline genotype and antiviral response to emtricitabine 200 mg QD among HBeAg positive patients with chronic hepatitis B infection [abstract 559]. In: Program and abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases (Boston, MA). 2004.
46. Snow A, Guan R, Diamandis G, et al. Correlation between baseline genotype and antiviral response to emtricitabine 200 mg QD among HBeAg negative patients with chronic hepatitis B infection [abstract 1133]. In: Program and abstracts of the 55th Annual Meeting of the American Association for the Study of Liver Diseases (Boston, MA). 2004.
47. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the international AIDS society-usa Panel. JAMA 2004; 292:251-65.
48. Department of Health and Human Services. Guidelines for the use of antiretroviral therapy in Adults. Available at: http://www.aidsinfo.nih .gov. Accessed on 10 November 2005.
49. Wellons MF, Bartlett JA. Emtricitabine. In: Dolin, Masur, Saag, eds. AIDS therapy. 2nd ed. Philadelphia: Elsevier Sciences, 2003:106